Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 9/30/2020 | 6/30/2020 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.01 | -0.00 | 0.03 |
| FCF Yield | -36.87% | -31.62% | -39.31% | -4.32% |
| EV / EBITDA | -3.76 | -5.36 | 1.10 | -22.27 |
| Quality | ||||
| ROIC | 32.59% | 14.17% | 9.87% | 4.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 1.20 | -0.54 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 30.08% | -118.18% | -135.98% | -301.25% |
| Safety | ||||
| Net Debt / EBITDA | -1.84 | -1.43 | -0.23 | -7.99 |
| Interest Coverage | -83.92 | -30.59 | -15.27 | -9.60 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -102,444.60 | -9,271.01 | 0.00 | 0.00 |